NGM Biopharmaceuticals Secures $105,999,996 Series E Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3cc6867c-0497-404d-9185-75ec0a45aee2 - Date
3/26/2015 - Company Name
NGM Biopharmaceuticals - Mailing Address
630 Gateway Blvd South San Francisco, CA 94080 USA - Company Description
NGM is a privately-held drug discovery company committed to the identification and development of transformational biologics for diabetes, obesity, muscle wasting and other cardiometabolic diseases. - Website
http://www.ngmbio.com - Transaction Type
Venture Equity - Transaction Amount
$105,999,996 - Transaction Round
Series E - Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities. - M&A Terms
- Venture Investor
